Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | KRAS | P01116 | 16/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.33 |
| ▸ | VHL | P40337 | 1/20 | 0.32 |
| ▸ | CDK7 | P50613 | 1/20 | 0.32 |
| ▸ | CCNH | P51946 | 1/20 | 0.32 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19637840 | 1.00 | PARP1 (0.35) | PARP1KRASNR1H2NR1H3VHL | |
| SCHEMBL19617060 | 1.00 | PARP1 (0.35) | PARP1KRASNR1H2NR1H3VHL | |
| SCHEMBL19948563 | 0.88 | KRAS (0.36) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL19948171 | 0.88 | KRAS (0.36) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL19637243 | 0.88 | KRAS (0.39) | PARP1KRASVHLCDK7CCNH | |
| SCHEMBL21315017 | 0.85 | KRAS (0.37) | KRASNR1H2NR1H3VHLCDK7 | |
| SCHEMBL21315015 | 0.85 | KRAS (0.37) | KRASNR1H2NR1H3VHLCDK7 | |
| SCHEMBL28500547 | 0.84 | IDH1 (0.41) | PARP1KRASVHLCDK7CCNH | |
| SCHEMBL29888410 | 0.84 | IDH1 (0.41) | PARP1KRASVHLCDK7CCNH | |
| SCHEMBL19948383 | 0.84 | IDH1 (0.41) | PARP1KRASVHLCDK7CCNH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230105745-A1 | CYCLOALKYL AND HETERO-CYCLOALKYL INHIBITORS, PREPARATION METHODS THEREFOR, AND USE THEREOF | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-04-06 | — | — | US | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11459327-B1 | Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and use thereof | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2022-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230105745-A1 | CYCLOALKYL AND HETERO-CYCLOALKYL INHIBITORS, PREPARATION METHODS THEREFOR, AND USE THEREOF | KRAS, NRAS, WEE1 | PARP1 912/4885KRAS 1/4885NR1H2 1254/4885 |
| US-11459327-B1 | Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and use thereof | KRAS, NRAS, WEE1 | PARP1 912/4885KRAS 1/4885NR1H2 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.